FDA clears Mauna Kea Technologies system for lung cancer detection - Mass Device

FDA clears Mauna Kea Technologies system for lung cancer detection  Mass Device

Paris-based Mauna Kea Technologies (ENT:MKEA) said that it has received 510(k) clearance from FDA for the use of the Cellvizio AQ-Flex 19 Confocal ...



Comments

Popular posts from this blog

Stage 4 Lung Cancer Life Expectancy

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...